Pharmafile Logo

Combination therapies in oncology: The benefits of integrated insights

14 June 2018
11am EDT | 8am PDT | 4pm BST | 5pm CE


In association with Pharmaceutical Executive

Register now: https://bit.ly/2L80Tme

Most experts believe combination therapies to be the future of oncology treatment. But with a number of new compounds approved and hundreds more in development, it’s difficult for many to identify which combinations and in what sequence, will form future treatment paradigms. In addition, the rising costs of newer agents and increased cost pressure creates an environment ripe for payer management.

In this webinar, pharma market research experts Anthony Greenwood, Dr Chris Gaj and  Brett Gardiner will look at the challenges and opportunities for effectively launching combination therapies across tumor types and, referencing their experience in oncology, demonstrate how integrated insights from payers, KOLs, community oncologists and patients can help support bio-pharma companies with oncology assets in all stages of clinical development.

Key Learning Objectives:

Delegates will:

  • Learn about the major themes, challenges and opportunities for marketing an oncology therapy in combination, including clinical trial design, pricing, sequencing and product attributes, amongst others
  • Understand implications of combining therapies from more than one manufacturer, anticipated pricing challenges and considerations for indication expansion
  • Understand the payer environment in oncology across the US and EU and uncover what evidence payers are looking for to make decisions about combination therapies
  • Understand how KOLs see oncology market evolving and how combination therapies will be utilized
  • Understand what effect patient characteristics may have on eventual treatment choice
  • Learn how integrated insights across all stakeholder groups can benefit launch strategies

Register now: https://bit.ly/2L80Tme

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Review of Disease Promotion Campaign using Facial Analysis

Our client had developed a visual and emotion-invoking, online disease awareness campaign aimed at challenging physicians’ current perceptions of treatment. Research was required to understand physicians’ reactions to the campaign...

Emotional Recognition using Facial Analysis

Do you have a poker face or does your expression give you away?  According to psychologists, a lot of emotional information can be drawn from our facial expressions, which is...

Living with NASH: An Unexpected Diagnosis

Published in eyeforpharma November 2017 by Mariel Metcalfe

20 questions: Round 7

As it's our 20th year anniversary, we invited our employees to play our version of 20 questions - this month "What project or event has been most memorable to you at RP?"Watch...

Innovation, sustainability and prosperity: Japan’s healthcare vision for the future

The vision for Japan 2035; A healthcare system that delivers unrivalled health outcomes, providing secure and responsive care for all members of society, sustainable, and contributing to prosperity in the...

Tools to action your segmentation

Our tools for ensuring a successful segmentation rollout

Research Partnership launches new patient Living with Atopic Dermatitis (US) 2017 report

Living with Atopic Dermatitis (AD) is a study conducted amongst 100 adults and 50 caregivers  in the US. The report will consist of 45-minute quantitative and 30-minute qualitative interviews with AD...

The value of design thinking: Incorporating creative and graphic design into pharma market research

How do we keep research design fresh and interesting? How do we ensure that we’re inspiring our respondents to give us enlightening new insights, and encourage new ways of thinking?There...

Research Partnership launches new patient Living with Psoriasis 2017 (EU) report

Living with Psoriasis is a study conducted amongst 615 patients in Europe. The report will consist of 30-minute online interviews with 600 patients and 15 qualitative interviews. It can be purchased...

Deep Dive – MINT: opportunities in ‘frontier’ markets?

According to British economist Jim O’Neill, MINT is the new BRIC. What is MINT? An acronym he coined for the ‘frontier’ markets of Mexico, Indonesia, Nigeria and Turkey. These are...